In the BioHarmony Drug Report Database
Elosulfase alfa
Vimizim (elosulfase alfa) is an enzyme pharmaceutical. Elosulfase alfa was first approved as Vimizim on 2014-02-14. It is used to treat mucopolysaccharidosis IV in the USA. It has been approved in Europe to treat mucopolysaccharidosis IV.
Trade Name
|
Vimizim |
|---|---|
Common Name
|
elosulfase alfa |
ChEMBL ID
|
CHEMBL2108676 |
Indication
|
mucopolysaccharidosis iv |
Drug Class
|
Enzymes |
Image (chem structure or protein)
